Antidepressants: Controversies about their efficacy in depression, their effect on suicidality and their place in a complex psychiatric treatment approach

References

• Anderson IM. Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability. J Affect Disord 2000; 58: 19–36
   PubMed Web of Science ®Google Scholar
• Angst J, Angst F, Gerber-Werder R, Gamma A. Suicide in 406 mood-disorder patients with and without long-term medication: a 40 to 44 years' follow-up. Arch Suicide Res 2005; 9: 279–300
   PubMedGoogle Scholar
• Baghai TC, Volz HP, Möller HJ. Drug treatment of depression in the 2000s: An overview of achievements in the last 10 years and future possibilities. World J Biol Psychiatry 2006; 7: 198–222
   PubMed Web of Science ®Google Scholar
• Balazs J, Benazzi F, Rihmer Z, Rihmer A, Akiskal KK, Akiskal HS. The close link between suicide attempts and mixed (bipolar) depression: implications for suicide prevention. J Affect Disord 2006; 91: 133–138
   PubMed Web of Science ®Google Scholar
• Baldwin D, Broich K, Fritze J, Kasper S, Westenberg H, Möller HJ. Placebo-controlled studies in depression: necessary, ethical and feasible. Eur Arch Psychiatry Clin Neurosci 2003; 253: 22–28
   PubMed Web of Science ®Google Scholar
• Bauer M, Whybrow PC, Angst J, Versiani M, Möller HJ, Task Force on Treatment Guidelines for Unipolar Depressive Disorders. WFSBP. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, Part 1: Acute and continuation treatment of major depressive disorder. World J Biol Psychiatry 2002; 3: 5–43
   PubMedGoogle Scholar
• Bauer M, Bschor T, Pfennig A, Whybrow PC, Angst J, Versiani M, et al. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders in Primary Care. World J Biol Psychiatry 2007; 8: 67–104
   PubMed Web of Science ®Google Scholar
• Bauer M, Tharmanathan P, Volz HP, Möller HJ, Freemantle N. The effect of venlafaxine compared with other antidepressants and placebo in the treatment of major depression: A meta-analysis. Eur Arch Psychiatry Clin Neurosci 2009; 259: 172–185
   PubMed Web of Science ®Google Scholar
• Beck AT, Rush AJ, Shaw BF. Cognitive therapy of depression. Guilford, New York 1979
   Google Scholar
• Belmaker RH, Agam G. Major depressive disorder. New Engl J Med 2008; 358: 55–68
   PubMed Web of Science ®Google Scholar
• Caspi A, Moffitt TE. Gene-environment interactions in psychiatry: joining forces with neuroscience. Nat Rev Neurosci 2006; 7: 583–590
   PubMed Web of Science ®Google Scholar
• Caspi A, Sugden K, Moffitt TE, Taylor A, Craig IW, Harrington H, et al. Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science 2003; 301: 386–389
   PubMed Web of Science ®Google Scholar
• Cuijpers P, van Straten A, Warmerdam L. Behavioral activation treatments of depression: a meta-analysis. Clin Psychol Rev 2007a; 27: 318–326
   PubMed Web of Science ®Google Scholar
• Cuijpers P, van Straten A, Warmerdam L. Problem solving therapies for depression: a meta-analysis. Eur Psychiatry 2007b; 22: 9–15
   PubMed Web of Science ®Google Scholar
• de Maat S, Dekker J, Schoevers R, van Aalst G, Gijsbers-van Wijk C, Hendriksen M, et al. Short psychodynamic supportive psychotherapy, antidepressants, and their combination in the treatment of major depression: a mega-analysis based on three randomized clinical trials. Depress Anxiety 2008; 25(7)565–574
   PubMed Web of Science ®Google Scholar
• Eser D, Baghai TC, Möller HJ. Evidence of agomelatine's antidepressant efficacy: the key points. Int Clin Psychopharmacol 2007; 22(Suppl 2)S15–19
   PubMedGoogle Scholar
• Eser D, Baghai T, Möller HJ. Agomelatine: the evidence for its place in the treatment of depression. Core Evidence 2008; 3(2)109–116
   Google Scholar
• FDA Public Health Advisory. Suicidality in children and adolescents being treated with antidepressant medications. 2004 < www.fda.gov/cder/drug/antidepressants/SSRIPHA200410.htm>.
   Google Scholar
• Fergusson D, Doucette S, Glass KC, Shapiro S, Healy D, Hebert P, et al. Association between suicide attempts and selective serotonin reuptake inhibitors: systematic review of randomised controlled trials. Br Med J 2005; 330: 396
   PubMed Web of Science ®Google Scholar
• Friedman MA, Detweiler-Bedell JB, Leventhal HW, Horne R, Keitner GI, Miller IW. Combined psychotherapy and pharmacotherapy for the treatment of depression disorder. Clin Psychol Sci Pract 2004; 11: 47–68
   Web of Science ®Google Scholar
• Fritze J, Möller HJ. Design of clinical trials of antidepressants. Should a placebo control arm be included?. CNS Drugs 2001; 15(10)755–764
   PubMed Web of Science ®Google Scholar
• Frodl T, Meisenzahl EM, Zill P, Baghai T, Rujescu D, Leinsinger G, et al. Reduced hippocampal volumes associated with the long variant of the serotonin transporter polymorphism in major depression. Arch Gen Psychiatry 2004; 61: 177–183
   PubMed Web of Science ®Google Scholar
• Frodl T, Moller HJ, Meisenzahl E. Neuroimaging genetics: new perspectives in research on major depression?. Acta Psychiatr Scand 2008; 118: 363–372
   PubMed Web of Science ®Google Scholar
• Geddes JR, Carney SM, Davies C, Furukawa TA, Kupfer DJ, Frank E, et al. Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review. Lancet 2003; 361: 653–661
   PubMed Web of Science ®Google Scholar
• Geddes JR, Cipriani A. Selective serotonin reuptake inhibitors. Br Med J 2004; 329: 809–810
   PubMed Web of Science ®Google Scholar
• Hammad, T. 2004. Review and evaluation of clinical data: Relationship between psychotropic drugs and pediatric suicidality. < www.fda.gov/OHRMS/DOCKETS/AC/04/briefing/2004-4065b1-10-TAB08-Hammads-Review.pdf>.
   Google Scholar
• Hammad TA, Laughren T, Racoosin J. Suicidality in pediatric patients treated with antidepressant drugs. Arch Gen Psychiatry 2006; 63: 332–339
   PubMed Web of Science ®Google Scholar
• Hegerl U, Gallinat J, Juckel G. Event-related potentials. Do they reflect central serotonergic neurotransmission and do they predict clinical response to serotonin agonists?. J Affect Disord 2001; 62: 93–100
   PubMed Web of Science ®Google Scholar
• Hegerl U, Plattner A, Moller HJ. Should combined pharmaco- and psychotherapy be offered to depressed patients? A qualitative review of randomized clinical trials from the 1990s. Eur Arch Psychiatry Clin Neurosci 2004; 254: 99–107
   PubMed Web of Science ®Google Scholar
• Hegerl, U, Hautzinger, M, Mergl, R, Kohnen, R, Schütze, M, Scheunemann, W, , et al. 2008. Effects of pharmaco-and psychotherapy in depressed primary care patients: A randomised, controlled trial including a patient choice arm. J Clin Psychiatry.
   PubMed Web of Science ®Google Scholar
• Henkel V, Seemuller F, Obermeier M, Adli M, Bauer M, Mundt C, et al. Does early improvement triggered by antidepressants predict response/remission? –Analysis of data from a naturalistic study on a large sample of inpatients with major depression. J Affect Disord 2009; 115: 439–449
   PubMed Web of Science ®Google Scholar
• Hirschfeld RM, Montgomery SA, Aguglia E, Amore M, Delgado PL, Gastpar M, et al. Partial response and nonresponse to antidepressant therapy: current approaches and treatment options. J Clin Psychiatry 2002; 63: 826–837
   PubMed Web of Science ®Google Scholar
• Kato T. Molecular genetics of bipolar disorder and depression. Psychiatry Clin Neurosci 2007; 61: 3–19
   PubMed Web of Science ®Google Scholar
• Keller MB. Rationale and options for the long-term treatment of depression. Hum Psychopharmacol 2002; 17(Suppl 1)S43–46
   PubMedGoogle Scholar
• Keller MB, Gelenberg AJ, Hirschfeld RM, Rush AJ, Thase ME, Kocsis JH, et al. The treatment of chronic depression, part 2: a double-blind, randomized trial of sertraline and imipramine. J Clin Psychiatry 1998; 59: 598–607
   PubMed Web of Science ®Google Scholar
• Keller MB, McCullough JP, Klein DN, Arnow B, Dunner DL, Gelenberg AJ, et al. A comparison of nefazodone, the cognitive behavioral-analysis system of psychotherapy, and their combination for the treatment of chronic depression. New Engl J Med 2000; 342: 1462–1470
   PubMed Web of Science ®Google Scholar
• Keller MB, Trivedi MH, Thase ME, Shelton RC, Kornstein SG, Nemeroff CB, et al. The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) Study: Outcomes from the 2-year and combined maintenance phases. J Clin Psychiatry 2007; 68: 1246–1256
   PubMed Web of Science ®Google Scholar
• Kendrick, T, Chatwin, J, Dowrick, C, Tylee, A, Morriss, R, Peveler, R, , et al. 2009. Randomised controlled trial to determine the clinical effectiveness and cost-effectiveness of selective serotonin reuptake inhibitors plus supportive care, versus supportive care alone, for mild to moderate depression with somatic symptoms in primary care: the THREAD (THREshold for AntiDepressant response) study. Health Technol Assess 13: iii–xi, 1.
   Google Scholar
• Kirsch, I, Moore, TJ, Scoboria, A, Nicholls, S. 2002. The emperor's new drugs: an analyses of antidepressant medication data submitted to the U.S. Food and Drug Administration. Prevention & Treatment 5(article 23).
   Google Scholar
• Kirsch I, Deacon BJ, Huedo-Medina TB, Scoboria A, Moore TJ, Johnson BT. Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration. PLoS Med 2008; 5: e45
   PubMed Web of Science ®Google Scholar
• Klein, DF. 1998. Listening to meta-analysis but hearing bias. Prevention & Treatment 1.
   Google Scholar
• Klerman GL, Weissmann MM. Interpersonal psychotherapy (IPT) and drugs in the treatment of depression. Pharmacopsychiatry. 1987; 20(1)3–7
   PubMed Web of Science ®Google Scholar
• Koran LM, Gelenberg AJ, Kornstein SG, Howland RH, Friedman RA, DeBattista C, et al. Sertraline versus imipramine to prevent relapse in chronic depression. J Affect Disord 2001; 65: 27–36
   PubMed Web of Science ®Google Scholar
• Lepine JP, Caillard V, Bisserbe JC, Troy S, Hotton JM, Boyer P. A randomized, placebo-controlled trial of sertraline for prophylactic treatment of highly recurrent major depressive disorder. Am J Psychiatry 2004; 161: 836–842
   PubMed Web of Science ®Google Scholar
• Lepola U, Wade A, Andersen HF. Do equivalent doses of escitalopram and citalopram have similar efficacy? A pooled analysis of two positive placebo-controlled studies in major depressive disorder. Int Clin Psychopharmacol 2004; 19: 149–155
   PubMed Web of Science ®Google Scholar
• Lerer B, Macciardi F. Pharmacogenetics of antidepressant and mood–stabilizing drugs: a review of candidate-gene studies and future research directions. Int J Neuropsychopharmacol 2002; 5: 255–275
   PubMed Web of Science ®Google Scholar
• Llorca PM, Azorin JM, Despiegel N, Verpillat P. Efficacy of escitalopram in patients with severe depression: a pooled analysis. Int J Clin Pract 2005; 59: 268–275
   PubMed Web of Science ®Google Scholar
• Mallinckrodt CH, Prakash A, Houston JP, Swindle R, Detke MJ, Fava M. Differential antidepressant symptom efficacy: placebo-controlled comparisons of duloxetine and SSRIs (fluoxetine, paroxetine, escitalopram). Neuropsychobiology 2007; 56: 73–85
   PubMed Web of Science ®Google Scholar
• Melander H, Salmonson T, Abadie E, Zwieten-Boot B. A regulatory apologia – A review of placebo-controlled studies in regulatory submissions of new-generation antidepressants. Eur Neuropsychopharmacol 2008; 18(9)623–627
   PubMed Web of Science ®Google Scholar
• Möller HJ. Antidepressants – do they decrease or increase suicidality?. Pharmacopsychiatry 1992a; 25: 249–253
   PubMed Web of Science ®Google Scholar
• Möller HJ. Attempted suicide: efficacy of different aftercare strategies. Int Clin Psychopharmacol 1992b; 6(Suppl 6)58–69
   PubMed Web of Science ®Google Scholar
• Möller HJ. Rating depressed patients: observer- vs self-assessment. Eur Psychiatry 2000; 15: 160–172
   PubMed Web of Science ®Google Scholar
• Möller HJ. Suicide, suicidality and suicide prevention in affective disorders. Acta Psychiatr Scand Suppl 2003; 418: 73–80
   Google Scholar
• Möller HJ. Therapieresistenz unipolarer depressiver Erkrankungen: Häufigkeit, Prädiktoren, Risikofaktoren. Akute und therapieresistente Depression2. Aufl. ed, M Bauer, A Berghöfer, M Adli. Springer, Heidelberg 2005; 21–38
   Google Scholar
• Möller HJ. Evidence for beneficial effects of antidepressants on suicidality in depressive patients: A systematic review. Eur Arch Psychiatry Clin Neurosc 2006a; 256: 329–343
   PubMed Web of Science ®Google Scholar
• Möller, HJ. 2006b. Pharmacological/clinical mechanisms by which antidepressants could theoretically induce suicidal ideations or behaviour. In preparation.
   Google Scholar
• Möller HJ. Is the identification of the core symptoms of depression clinically relevant?. Medicographia 2008a; 30: 3–8
   Google Scholar
• Möller HJ. Is there a need for a new psychiatric classification at the current state of knowledge?. World J Biol Psychiatry 2008b; 9: 82–85
   PubMed Web of Science ®Google Scholar
• Möller HJ. Isn't the efficacy of antidepressants clinically relevant? A critical comment on the results of the meta-analysis by Kirsch et al. 2008. Eur Arch Psychiatry Clin Neurosci. 2008c; 258(8)451–5
   PubMed Web of Science ®Google Scholar
• Möller HJ. Methodik empirischer Forschung. Psychiatrie und Psychotherapie3. Aufl. Band 1 ed, HJ Möller, G Laux, H-P Kapfhammer. Springer, Heidelberg 2008d; 346–367
   Google Scholar
• Möller HJ. Outcomes in major depressive disorder: The evolving concept of remission and its implications for treatment. World J Biol Psychiatry 2008e; 9: 102–114
   PubMed Web of Science ®Google Scholar
• Möller HJ. Standardised rating scales in Psychiatry: Methodological basis, their possibilities and limitations and descriptions of important rating scales. World J Biol Psychiatry 2009; 10: 6–26
   PubMed Web of Science ®Google Scholar
• Möller HJ, Maier W. Probleme der “evidence-based medicine” in der Psychopharmakotherapie. Problematik der Evidenzgraduierung und der Evidenzbasierung komplexer klinischer Entscheidungsprozesse. Nervenarzt 2007; 78: 1014–1027
   PubMed Web of Science ®Google Scholar
• Möller, HJ, Maier, W. 2009. Evidence-based Medicine in Psychiatry. Eur Arch Psychiatry Clin Neurosci, in press.
   Web of Science ®Google Scholar
• Möller HJ, von Zerssen D. Self-rating procedures in the evaluation of antidepressants. Psychopathology 1995; 28: 291–306
   PubMed Web of Science ®Google Scholar
• Möller HJ, Fischer G, von Zerssen D. Prediction of therapeutic response in acute treatment with antidepressants. Results of an empirical study involving 159 endogenous depressive inpatients. Eur Arch Psychiatry Neurol Sci 1987; 236: 349–357
   PubMedGoogle Scholar
• Möller HJ, Langer S, Schmauss M. Escitalopram in clinical practice: results of an open-label trial in outpatients with depression in a naturalistic setting in Germany. Pharmacopsychiatry 2007; 40: 53–57
   PubMed Web of Science ®Google Scholar
• Möller HJ, Baldwin DS, Goodwin G, Kasper S, Okasha A, Stein DJ, et al. Do SSRIs or antidepressants in general increase suicidality? WPA Section on Pharmacopsychiatry: consensus statement. Eur Arch Psychiatry Clin Neurosci 2008; 258(Suppl 3)3–23
   PubMedGoogle Scholar
• Moncrieff J, Kirsch I. Efficacy of antidepressants in adults. Br Med J 2005; 331: 155–157
   PubMed Web of Science ®Google Scholar
• Montgomery SA, Kasper S. Severe depression and antidepressants: focus on a pooled analysis of placebo-controlled studies on agomelatine. Int Clin Psychopharmacol 2007; 22: 283–291
   PubMed Web of Science ®Google Scholar
• Montgomery SA, Möller HJ. Is the significant superiority of escitalopram compared with other antidepressants clinically relevant?. Int Clin Psychopharmacol 2009; 24: 111–118
   PubMed Web of Science ®Google Scholar
• Montgomery SA, Bech P, Blier P, Möller HJ, Nierenberg AA, Pinder RM, et al. Selecting methodologies for the evaluation of differences in time to response between antidepressants. J Clin Psychiatry 2002; 63: 694–699
   PubMed Web of Science ®Google Scholar
• Montgomery SA, Baldwin DS, Blier P, Fineberg NA, Kasper S, Lader M, et al. Which antidepressants have demonstrated superior efficacy? A review of the evidence. Int Clin Psychopharmacol 2007; 22: 323–329
   PubMed Web of Science ®Google Scholar
• National Institute for Clinical Excellence. 2004. Depression: management of depression in primary and secondary care. Clinical practice guideline No 23. London: National Institute for Clinical Excellence.
   Google Scholar
• Papakostas GI, Thase ME, Fava M, Nelson JC, Shelton RC. Are antidepressant drugs that combine serotonergic and noradrenergic mechanisms of action more effective than the selective serotonin reuptake inhibitors in treating major depressive disorder? A meta-analysis of studies of newer agents. Biol Psychiatry 2007; 62: 1217–1227
   PubMed Web of Science ®Google Scholar
• Parker G. Classifying depression: should paradigms lost be regained?. Am J Psychiatry 2000; 157: 1195–1203
   PubMed Web of Science ®Google Scholar
• Parker G. Differential effectiveness of newer and older antidepressants appears mediated by an age effect on the phenotypic expression of depression. Acta Psychiatr Scand 2002; 106: 168–170
   PubMed Web of Science ®Google Scholar
• Paykel ES. Cognitive therapy in relapse prevention in depression. Int J Neuropsychopharmacol 2007; 10: 131–136
   PubMed Web of Science ®Google Scholar
• Paykel ES, Scott J, Teasdale JD, Johnson AL, Garland A, Moore R, et al. Prevention of relapse in residual depression by cognitive therapy: a controlled trial. Arch Gen Psychiatry 1999; 56: 829–835
   PubMed Web of Science ®Google Scholar
• Reynolds CF III, Dew MA, Pollock BG, Mulsant BH, Frank E, Miller MD, et al. Maintenance treatment of major depression in old age. New Engl J Med 2006; 354: 1130–1138
   PubMed Web of Science ®Google Scholar
• Rush AJ. STAR*D: what have we learned?. Am J Psychiatry 2007; 164: 201–204
   PubMed Web of Science ®Google Scholar
• Rush AJ, Koran LM, Keller MB, Markowitz JC, Harrison WM, Miceli RJ, et al. The treatment of chronic depression, part 1: study design and rationale for evaluating the comparative efficacy of sertraline and imipramine as acute, crossover, continuation, and maintenance phase therapies. J Clin Psychiatry 1998; 59: 589–597
   PubMed Web of Science ®Google Scholar
• Sanchez C, Bogeso KP, Ebert B, Reines EH, Braestrup C. Escitalopram versus citalopram: the surprising role of the R-enantiomer. Psychopharmacology (Berlin) 2004; 174: 163–176
   PubMed Web of Science ®Google Scholar
• Schaub A, Roth E, Goldmann U. Kognitiv-Psychoedukative Therapie zur Bewältigung von Depressionen: Ein Therapiemanual. Hogrefe, Göttingen 2006
   Google Scholar
• Schechter LE, Ring RH, Beyer CE, Hughes ZA, Khawaja X, Malberg JE, et al. Innovative approaches for the development of antidepressant drugs: current and future strategies. NeuroRx 2005; 2: 590–611
   PubMedGoogle Scholar
• Seemüller F, Riedel M, Obermeier M, Bauer M, Adli M, Mundt C, et al. The controversial link between antidepressants and suicidality risks in adults: data from a naturalistic study on a large sample of in-patients with a major depressive episode. Int J Neuropsychopharmacol 2009; 12: 181–189
   PubMed Web of Science ®Google Scholar
• Sharan P, Saxena S. Treatment-resistant depression: clinical significance, concept and management. Natl Med J India 1998; 11: 69–79
   PubMed Web of Science ®Google Scholar
• Stassen HH, Angst J, Hell D, Scharfetter C, Szegedi A. Is there a common resilience mechanism underlying antidepressant drug response? Evidence from 2848 patients. J Clin Psychiatry 2007; 68: 1195–1205
   PubMed Web of Science ®Google Scholar
• Stone, MB, Jones, ML. 2006. Clinical review: Relationship between antidepressant drugs and suicidality in adults. < www.fda.gov/OHRMS/DOCKETS/AC/06/briefing/2006-4272b1-01-FDA.pdf>.
   Google Scholar
• Storosum JG, Elferink AJ, van Zwieten BJ, van den BW, Gersons BP, van Strik R, et al. Short-term efficacy of tricyclic antidepressants revisited: a meta-analytic study. Eur Neuropsychopharmacol 2001; 11: 173–180
   PubMed Web of Science ®Google Scholar
• Sullivan PF, Neale MC, Kendler KS. Genetic epidemiology of major depression: review and meta-analysis. Am J Psychiatry 2000; 157: 1552–1562
   PubMed Web of Science ®Google Scholar
• Tadic A, Muller MJ, Rujescu D, Kohnen R, Stassen HH, Dahmen N, et al. The MAOA T941G polymorphism and short-term treatment response to mirtazapine and paroxetine in major depression. Am J Med Genet B Neuropsychiatr Genet 2007; 144B: 325–331
   PubMed Web of Science ®Google Scholar
• Teicher MH, Glod CA, Cole JO. Antidepressant drugs and the emergence of suicidal tendencies. Drug Safety 1993; 8: 186–212
   PubMed Web of Science ®Google Scholar
• Thase ME, Entsuah AR, Rudolph RL. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br J Psychiatry 2001; 178: 234–241
   PubMed Web of Science ®Google Scholar
• Thase ME, Rush AJ, Howland RH, Kornstein SG, Kocsis JH, Gelenberg AJ, et al. Double-blind switch study of imipramine or sertraline treatment of antidepressant-resistant chronic depression. Arch Gen Psychiatry 2002; 59: 233–239
   PubMed Web of Science ®Google Scholar
• Thase ME, Pritchett YL, Ossanna MJ, Swindle RW, Xu J, Detke MJ. Efficacy of duloxetine and selective serotonin reuptake inhibitors: comparisons as assessed by remission rates in patients with major depressive disorder. J Clin Psychopharmacol 2007; 27: 672–676
   PubMed Web of Science ®Google Scholar
• Toprac MG, Dennehy EB, Carmody TJ, Crismon ML, Miller AL, Trivedi MH, et al. Implementation of the Texas Medication Algorithm Project patient and family education program. J Clin Psychiatry 2006; 67: 1362–1372
   PubMed Web of Science ®Google Scholar
• Trindade E, Menon D, Topfer LA, Coloma C. Adverse effects associated with selective serotonin reuptake inhibitors and tricyclic antidepressants: a meta-analysis. CMAJ 1998; 159: 1245–1252
   PubMed Web of Science ®Google Scholar
• Trivedi MH, Rush AJ, Crismon ML, Kashner TM, Toprac MG, Carmody TJ, et al. Clinical results for patients with major depressive disorder in the Texas Medication Algorithm Project. Arch Gen Psychiatry 2004; 61: 669–680
   PubMed Web of Science ®Google Scholar
• Trivedi MH, Rush AJ, Wisniewski SR, Nierenberg AA, Warden D, Ritz L, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry 2006; 163: 28–40
   PubMed Web of Science ®Google Scholar
• Turner EH, Matthews AM, Linardatos E, Tell RA, Rosenthal R. Selective publication of antidepressant trials and its influence on apparent efficacy. New Engl J Med 2008; 358: 252–260
   PubMed Web of Science ®Google Scholar
• Vaiva G, Vaiva G, Ducrocq F, Meyer P, Mathieu D, Philippe A, et al. Effect of telephone contact on further suicide attempts in patients discharged from an emergency department: randomised controlled study. Br Med J 2006; 332: 1241–1245
   PubMed Web of Science ®Google Scholar
• Volz HP, Baghai TC, Möller HJ. Drug treatment of depression in the 2000s – an overview of achievements in the last ten years and future possibilities. World J Biol Psychiatry 2006; 7: 198–222
   PubMed Web of Science ®Google Scholar
• Zobel AW, Nickel T, Kunzel HE, Ackl N, Sonntag A, Ising M, Holsboer F. Effects of the high-affinity corticotropin-releasing hormone receptor 1 antagonist R121919 in major depression: the first 20 patients treated. J Psychiatr Res 2000; 34: 171–181
   PubMed Web of Science ®Google Scholar